Abstract
To the Editor: CD30 is a tumor necrosis factor receptor involved in regulating apoptosis and proliferation of CD30+ tumor cells.1 CD30+ T cells are primarily expressed in conditions such as primary cutaneous CD30+ T-cell lymphoproliferative disorders and some peripheral T-cell lymphomas, and they can potentially be expressed in any type of cutaneous T-cell lymphoma (CTCL).2-4 However, CD30 expansion on the leukemic cells of patients with CTCL or Sézary syndrome is rare, and little is known regarding the natural history and prognosis of patients with leukemic CTCL expressing this cell type.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
